Strategy, formerly MicroStrategy, repurchased $193 million of its stock and acquired 267 Bitcoin, increasing its total Bitcoin holdings to 848,517 BTC. The company also expanded its Digital Credit Securities Repurchase Program from $2 billion to $3 billion, signaling strong confidence in its asset strategy. These moves position Strategy as a major corporate Bitcoin holder and may influence its stock price toward $100 by the end of 2026. Investors will watch for further repurchases and Bitcoin price changes as key factors affecting the company's outlook.
Strategy repurchases and Bitcoin acquisition news provide market context. For readers following cryptocurrency, here is Pluang's market snapshot as of Oct 19, 2026 19:21 WIB: Out of 50 major cryptocurrencies, 23 rose and 25 fell today. CRV rose 3.99% to Rp6.334 with 57% buy orders, XNO dropped 3.61% to Rp5.847 with 100% buy orders, and ONE fell 3.61% to Rp25 with 52% sell orders.
Nyxoah announced preliminary Q3 2026 revenue of €9.2 million, up 19% sequentially, driven by a 29% increase in U.S. sales. The company submitted a PMA supplement to the FDA to expand its Genio device indication for patients with complete concentric c...
ASML Holding N.V. announced recent transactions under its ongoing share buyback program, repurchasing a total of 233,867 shares between October 12 and October 16, 2026. The shares were bought back at weighted average prices ranging from €1,444.83 to ...
The Phase 3 ALKIVIA trial demonstrated that efgartigimod significantly improves symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). Patients showed meaningful clinical improve...
In 2025, Berkshire Hathaway, led by Greg Abel, received $479 million in dividends from its $1.3 billion investment in American Express. This highlights the value of holding strong dividend-paying stocks for steady income. Retail investors can apply s...
Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...
